10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from                     to                     .

Commission file number:  0-15586

U.S. NeuroSurgical Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware	47-5370333
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

2400 Research Blvd, Suite 325, Rockville, Maryland 20850

(Address of principal executive offices)

(301) 208-8998

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes ☒          No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company, and “emerging growth company” in Rule 12b-2 of the Exchange Act.  (Check one):

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
(do not check if a smaller reporting company)	Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes ☐          No  ☒

The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of March 31, 2022 was 7,792,185.

Table of Contents

PART I - FINANCIAL INFORMATION		3
	Item 1.  Financial Statements	3
	Item 2.  Management Discussion and Analysis of Financial Condition and Results of Operations.	15
	Item 3.  Quantitative and Qualitative Disclosures About Market Risk.	19
	Item 4.  Controls and Procedures	20
PART II – OTHER INFORMATION		21
	Item 1.  Legal Proceedings	21
	Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds	21
	Item 3.  Defaults Upon Senior Securities	21
	Item 4.  Submission of Matters to a Vote of Security Holders	22
	Item 5.  Other Information	22
	Item 6.  Exhibits	22
SIGNATURES		23

2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2022 (Unaudited)			December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	1,658,000		$	2,178,000
Other current assets		47,000			65,000
Total current assets		1,705,000			2,243,000
Other assets:
Due from related parties		965,000			930,000
Investments in unconsolidated entities		146,000			141,000
Goodwill		315,000			315,000
Total other assets		1,426,000			1,386,000
Property and equipment:
Operating lease right-of-use asset		49,000			59,000
Total property and equipment		49,000			59,000
TOTAL ASSETS	$	3,180,000		$	3,688,000
LIABILITIES
Current liabilities:
Operating lease right-of-use liability - current portion	$	44,000		$	43,000
Accounts payable and accrued expenses		177,000			170,000
Income taxes payable		403,000			114,000
Total current liabilities		624,000			327,000
Operating lease right-of-use liability - net of current portion		12,000			23,000
Guarantee liability		11,000			11,000
Total liabilities		647,000			361,000
EQUITY
Common stock - par value $0.01; 25,000,000 shares authorized; 7,792,185 shares issued and outstanding at March 31, 2022 and December 31, 2021.		78,000			78,000
Additional paid-in capital		2,871,000			2,871,000
Accumulated deficit		(794,000	)		(119,000	)
U.S. NeuroSurgical Holdings Inc. stockholders’ equity		2,155,000			2,830,000
Noncontrolling interests		378,000			497,000
Total equity		2,533,000			3,327,000
TOTAL LIABILITIES AND EQUITY	$	3,180,000		$	3,688,000

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

3

U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended March 31,
	2022			2021
				(As Restated)
Revenue	$	-		$	1,061,000
Costs and expenses:
Patient expenses		-			86,000
Selling, general and administrative		360,000			298,000
Total		360,000			384,000
Operating (loss) income		(360,000	)		677,000
Total other (expense) income
Interest expense		-			(2,000	)
Interest income - sales-type sublease		-			8,000
Loss from investments in unconsolidated entities, net		(133,000	)		(139,000	)
Total other expense		(133,000	)		(133,000	)
(Loss) income before income taxes		(493,000	)		544,000
Provision for income taxes		2,000			252,000
Net (loss) income		(495,000	)		292,000
Net loss attributable to noncontrolling interests		74,000			-
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc.	$	(421,000	)	$	292,000
Basic and diluted net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc.	$	(0.05	)	$	0.04
Weighted average common shares outstanding, basic and diluted		7,792,185			7,792,185

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

4

U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Three Months Ended March 31,
	2022			2021
				(As Restated)
Cash flows from operating activities:
Net (loss) income	$	(495,000	)	$	292,000
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Amortization of operating lease right-of-use asset		10,000			8,000
Loss from investments in unconsolidated entities, net		133,000			139,000
Distributed earnings from unconsolidated entities		11,000			-
Deferred income taxes		-			-
Changes in:
Accounts receivable		-			(482,000	)
Income taxes receivable/payable		(11,000)			252,000
Other current assets		18,000			19,000
Accounts payable and accrued expenses		8,000			(4,000	)
Operating lease right-of-use liability		(10,000	)		(10,000	)
Net cash (used in) provided by operating activities		(336,000	)		214,000
Cash flows from investing activities:
Advances to unconsolidated entities		(182,000	)		(144,000	)
Captial contributions to unconsolidated entities		(2,000	)		-
Principal payments received under sales-type sublease		-			532,000
Net cash (used in) provided by  investing activities		(184,000	)		388,000
Cash flows from financing activities:
Repayment of finance lease obligations		-			(89,000	)
Net cash used in financing activities		-			(89,000	)
Net change in cash and cash equivalents		(520,000	)		513,000
Cash and cash equivalents - beginning of period		2,178,000			2,030,000
Cash and cash equivalents - end of period	$	1,658,000		$	2,543,000
Supplemental disclosures of cash flow information:
Cash paid for:
Interest	$	-		$	2,000

The accompanying notes to condensed consolidated financial statements are an integral part hereof.

5

U.S. NEUROSURGICAL HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note A - Basis of Preparation

The accompanying Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and Subsidiaries (the “Company”) as of March 31, 2021, and 2020, are unaudited.  However, in the opinion of management, such statements include all adjustments necessary for a fair statement of the information presented therein.  The Consolidated Balance Sheet at December 31, 2021, has been derived from the audited Consolidated Financial Statements at that date appearing in the Company’s Annual Report on Form 10-K.

Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements.  Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements.

Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years.  The only change to the Company’s equity in the three months ended March 31, 2022, and 2021 was net (loss) income for the periods.

The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation to noncontrolling interests in consolidated financial statements.  The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent’s equity and purchases and sales of equity interests, that do not result in a change in control, to be accounted for as equity transactions.  In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income.

The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification (“ASC”) Topic 842, Leases.

The Company primarily generated revenue, in 2021, from a leasing arrangement with New York University, which is not within the scope of Revenue from Contracts with Customers (Topic 606), and from the sale of maintenance, under the same agreement, with a single performance obligation. The NYU agreement ended in March 2021.

6

The tables below present financial information associated with our leases.

	Classification	March 31, 2022		March 31, 2021
Assets
Long-term
Operating lease assets	Operating lease right-of-use asset	$	49,000	$	86,000
Total leased assets		$	49,000	$	86,000
Liabilities
Current
Operating lease liabilities	Operating lease right-of-use liability - current portion	$	44,000	$	40,000
Long-term
Operating lease liabilities	Operating lease right-of-use liability - net of current portion	$	12,000	$	56,000
Total lease liabilities		$	56,000	$	96,000
Lease Cost
Operating lease cost	Selling, general and administrative	$	10,000	$	11,000
Finance lease cost
Interest on lease liabilities	Interest expense		-		2,000
Sublease income	Interest income - sales-type sublease		-		8,000
Net lease expense		$	10,000	$	5,000

Maturity of lease liabilities (as of March 31, 2022)	Operating lease
2022		33,000
2023		25,000
Total	$	58,000
Less amount representing interest		2,000
Present value of lease liabilities	$	56,000
Discount rate		5.850	%

7

Note B – Gamma Knife at NYU Medical Center

U.S. NeuroSurgical, Inc. (“USN”), a wholly-owned subsidiary of U.S. NeuroSurgical Holdings, Inc., opened a New York gamma knife treatment center in July 1997 on the campus of New York University (“NYU”) Medical Center.   The Company’s contract with NYU, its only customer, ended in March 2021.  Upon termination of the NYU contract, the Company recognized a gain of $100,000 relating to previously accrued expenses.  This gain was included as a reduction in selling, general and administrative expense in the quarter ended March 31, 2021.  The Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $1.6 million at March 31, 2022, will allow the Company the opportunity do so.  Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.  In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.

Note C – The Southern California Regional Gamma Knife Center

During 2007, the Company, through a noncontrolling interest in joint ventures, managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California.  Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife.  CGK leases the gamma knife from NeuroPartners LLC, which holds the gamma knife equipment.  In addition to returns on its ownership interests, USNC expects to receive fees for management services relating to the facility.

USNC is a 20% owner of NeuroPartners LLC and owns 39% of CGK.

USNC was a 20% guarantor on NeuroPartners LLC’s seven-year lease with respect to the gamma knife equipment and certain leasehold improvements at SARH.  In February 2016, NeuroPartners LLC negotiated a new five-year lease to fund the reloading of cobalt and related construction services.  The new lease of $1,663,000 included a balance of $668,000 from the prior lease obligations.  This new lease was payable over 60 months.  The first payment of $31,000 was paid in April 2016 and the final payment was paid in March 2021, removing USNC’s guarantee obligation.

Construction of the SARH gamma knife center was completed in December 2008 and the first patient was treated in January 2009.  The project has been funded principally by outside investors.  While the Company, through its joint ventures, has led the effort in organizing the business and overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal.

At March 31, 2022 and December 31, 2021, the Company’s recorded investment (loss) of NeuroPartners LLC and CGK was $0 and ($10,000), respectively. For the three months ended March 31, 2022, the Company’s equity in income of NeuroPartners LLC and CGK was $10,000 and compared to equity in loss of ($2,000) for the three months ended March 31, 2021.  At March 31, 2022, and December 31, 2021, amounts due from related parties was $19,000 and $6,000, respectively.

8

The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:

NeuroPartners LLC and CGK Condensed Combined Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	122,000		$	166,000
Net (loss) income	$	(30,000	)	$	19,000
USNC’s equity in income (loss) of NeuroPartners LLC and CGK	$	10,000		$	(2,000	)

NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information

	March 31, 2022		December 31, 2021
Current assets	$	368,000	$	299,000
Noncurrent assets		230,000		294,000
Total assets	$	598,000	$	593,000
Current liabilities	$	598,000	$	564,000
Noncurrent liabilities		-		-
Equity		-		29,000
Total liabilities and equity	$	598,000	$	593,000

9

Note D – Florida Oncology Partners

During 2010, through the formation of a joint venture, in which it has a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. In 2010, the Company formed FOP in partnership with local physicians and other investors.  USNC owned a 24% interest in the venture. FOP abandoned its operations on June 28, 2019, due to continued losses at the site and lack of success in good faith efforts to renegotiate the agreement after several months of discussion. Due to the circumstances, FOP derecognized the associated assets and liabilities and calculated a contingent liability equal to the net liabilities derecognized. On November 24, 2021, the third-party owner filed a Voluntary Motion to Dismiss their lawsuit against FOP, and on December 11, 2021, it was accepted and recorded by the court. There can be no guarantee the third-party owner will not reinstitute any future claims against FOP.

The Company’s recorded investment in FOP prior to dissolution had been reduced to zero due to losses incurred in prior years. No equity in earnings had been recorded by the Company due to FOP’s deficit equity.

On September 21, 2021, FOP filed Articles of Dissolution with the Florida Department of State that were recorded on September 22, 2021. FOP is fully dissolved.

Note E – Boca Oncology Partners

During the quarter ended June 30, 2011, the Company, through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida.  In June 2011, Boca Oncology Partners RE, LLC (“BOPRE”,) an affiliated entity, purchased a 20% interest in Boca West IMP, owner of a medical office building in West Boca, Florida in which BOP operates.  BOP occupies 6,000 square feet of the 32,000 square foot building.  The Company invested $225,000 initially and had a 22.5% interest in BOP and BOPRE. In February 2014, the Company and other members sold their interests in BOP.

In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP.

During the years ended December 31, 2018 and 2017, several investors relinquished part of their ownership interest in BOPRE, and those interests were distributed among the remaining investors in relationship to their percentages owned. During 2021 and 2022 additional members relinquished its ownership to USNC. As a result, the Company now holds a 24.36% ownership interest in BOPRE, which it accounts for under the equity method. The Company’s recorded investment in BOPRE is $145,000 and $151,000 at March 31, 2022 and December 31, 2021, respectively.

10

The following tables present the summarized financial information of BOPRE:

BOPRE Condensed Income Statement Information

	Three Months Ended March 31,
	2022			2021
Rental Income		$	-		$	-
Net income		$	17,000		$	18,000
USNC’s equity in earnings of BOPRE		$	4,000		$	3,000

BOPRE Condensed Balance Sheet Information

	March 31, 2022		December 31, 2021
Current assets	$	80,000	$	112,000
Noncurrent assets		757,000		757,000
Total assets	$	837,000	$	869,000
Current liabilities	$	-	$	-
Noncurrent liabilities		-		-
Equity		837,000		869,000
Total liabilities and equity	$	837,000	$	869,000

11

Note F - Medical Oncology Partners

In April 2015, MOP, was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in UOMA. USNC was not a member of MOP at the time of formation as it was not able to participate due to the fact that USNC was not a physician. Nevertheless, USNC wished to eventually obtain an equity interest in MOP and loaned Dr. Jaime Lozano, the principal investor in MOP and a co-investor in FOP, $173,000.  Dr. Lozano used these funds, along with an equal amount of his own funds (a total of $345,000), to purchase a 76.67% interest in MOP. Other investors paid a further $105,000 for the remaining equity in MOP. MOP used the $450,000 of financing to acquire a 100% equity interest in UOMA.  An application was filed for a waiver to allow USNC to hold an equity interest notwithstanding the physician requirement and on December 22, 2016, USNC was cleared to become a part owner of MOP. Dr. Lozano agreed to exchange half of his membership interest to USNC in settlement of the note to USNC.  USNC and Dr. Lozano also agreed to share equally in providing a 5% equity interest in MOP to an additional investor as a consulting fee for services rendered in the administration of MOP and UOMA. At December 22, 2016, USNC owned 35.83% of MOP with an initial carrying value of $161,000. The Company recorded its share of losses of $12,000 for the period from December 22, 2016 to December 31, 2016, against its investment which resulted in a reduction of its equity investment to $149,000.

Due to increasing costs, continued net losses since April 2015, and reliance on related party and other debt for operating cash flows, the fair value of UOMA is less than its carrying amount. The Company tested its investment for impairment at December 31, 2016 and determined that the investment was impaired, and an impairment loss was recorded against the entire equity balance in MOP, as well as loans from USN and USNC to MOP and UOMA. For the three months ended March 31, 2022 and 2021, the Company’s equity in loss of MOP was $39,000 and $60,000, respectively, but was not recorded due to prior losses.

During the three months ended March 31, 2022 and 2021, the Company advanced $99,600 and $141,000, all of which has been fully impaired. These allowances and write offs were recorded as losses from investments in unconsolidated entities.

Due to loans made to MOP and UOMA, MOP and UOMA are considered to be variable interest entities of the Company.  However, as the Company is not deemed to be the primary beneficiary of MOP or UOMA, since it does not have the power to direct the operating activities that most significantly affect MOP’s or UOMA’s economic performance, the entities are not consolidated, but certain disclosures are provided herein.

12

The following table presents the summarized financial information of MOP:

MOP Condensed Consolidated Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	533,000		$	537,000
Net loss	$	(188,000	)	$	(168,000	)
USNC’s equity in loss of MOP	$	(39,000	)	$	(60,000	)

MOP Condensed Consolidated Balance Sheet Information

	March 31, 2022			December 31, 2021
Current assets	$	277,000		$	201,000
Noncurrent assets		300,000			384,000
Total assets	$	577,000		$	585,000
Current liabilities	$	3,229,000		$	3,109,000
Noncurrent liabilities		78,000			92,000
Deficit		(2,730,000	)		(2,616,000	)
Total liabilities and deficit	$	577,000		$	585,000

Note G - CB Oncology Partners

CBOP was organized September 1, 2017, to acquire the rights of the new center from FOP. USNC originally had a 24% equity interest in CBOP.  Beginning in October of 2017, CBOP began paying the remainder of the costs associated with opening the center. The medical center opened and treated its first patient in January of 2018.

Effective November 15, 2019, FOP transferred to, and CBOP assumed, a loan with BB&T bank, that it had entered into in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and extended the loan to July of 2027.

In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously-made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions are not expected to be met and, accordingly, the Company’s equity interest in CBOP increased to 28.58% in June 2020.

13

Amounts due from CBOP at March 31, 2022, total $2,208,000 of outstanding principal, less $1,289,000 of allowances, for a net receivable of $919,000 all of which is included in due from related parties on the accompanying Condensed Consolidated Balance Sheets. Amounts due from CBOP at December 31, 2021, total $2,174,000 of outstanding principal, less $1,251,000 of allowances, for a net receivable of $923,000 all of which is included in due from related parties on the accompanying Condensed Consolidated Balance Sheets. These balances accrue interest at 6% per annum. Interest earned by the Company from the amounts owed by CBOP totaled $29,000 and $31,000 for the three months ended March 31, 2022 and 2021, respectively. At March 31, 2022 and December 31, 2021, total accrued interest was $427,000 and $398,000, respectively, all of which has been fully reserved for. The Company recorded increases in the allowance as a component of loss from investments in unconsolidated entities and as a deduction in interest income for interest earned.

Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company.  However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic performance, the entity is not consolidated, but certain disclosures are provided herein.

The following table presents the summarized financial information of CBOP:

CBOP Condensed Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	582,000		$	471,000
Net (loss) income	$	(46,000	)	$	62,000
USNC’s equity in (loss) income of CBOP	$	(13,000	)	$	18,000

CBOP Condensed Balance Sheet Information

	March 31, 2022			December 31, 2021
Current assets	$	582,000		$	400,000
Noncurrent assets		3,515,000			3,667,000
Total assets	$	4,097,000		$	4,067,000
Current liabilities	$	3,533,000		$	3,472,000
Noncurrent liabilities		3,125,000			3,121,000
Deficit		(2,561,000	)		(2,526,000	)
Total liabilities and deficit	$	4,097,000		$	4,067,000

14

Note H – Elite Health

Effective October 1, 2021, U.S. NeuroSurgical, Inc. (“USN”), acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation (“Elite Health”.) The transaction with Elite Health was structured as an investment by Elite Health shareholders in USN, and as such did not have an immediate effect on the percentage ownership of the shareholders of the Company.  However, the Company’s interest in USN, which currently holds substantially all of the interest in the Company’s businesses and operations, was effectively diluted by 15% as a result of the issuance of the new USN shares to the former holders of Elite Health.  In addition, pursuant to the terms of this transaction, the former shareholders of Elite Health may request that the Company take steps that would give such holders access to the public trading market.  If this is requested by the Elite Health holders, it could be accomplished at the Company’s election through an exchange of such holders’ shares in USN for common stock of the Company.

Elite Health is a private company with a limited operating history.  It was formed in 2017 with the purpose of establishing a managed care organization that will operate as a Medicare Advantage plan for seniors.  It is expected that Elite Health will operate in California, initially San Bernadino, Riverside, and Orange Counties, with the objective of addressing the growing number of Medicare eligible seniors in those markets.

Elite Health is in the process of applying for a Knox Keene license to operate a Medicare Advantage plan in California and has taken preliminary steps toward identifying a network of providers who are well-versed in the healthcare needs of seniors in the communities in which they practice.  If Elite Health is successful in obtaining the license, establishing Elite Health as an operating entity will require significant investment not currently available to the Company.  The Company is currently exploring opportunities to provide the necessary funding to proceed with activities required to launch Elite Health.

Note I – Income Taxes

The Company’s income tax rate, which includes federal and state income taxes, was approximately 1%, for the three months ended March 31, 2022, and 2021. The Company recorded a tax provision of $2,000 and $252,000 (restated) for the three months ended March 31, 2022, and 2021, respectively.

15

Note J - Restatement of Previously Issued Financial Statements

During the quarter ended March 31, 2022, the Company determined that in March 2021, pursuant to an agreement with New York University ("NYU"), ownership of all of the gamma knife equipment at the NYU Medical Center transferred from the Company to NYU, resulting in the recognition of a gain on the sale and transfer of the gamma knife property on the Company's December 31, 2021 income tax returns. The Company previously received insurance proceeds with the Gamma Knife facility, which was destroyed as a result of flooding from Hurricane Sandy. For tax purposes, the resulting gain becomes taxable when the replacement property is sold or disposed of, which occurred in 2021. As a result, the Company recorded this tax liability and restated its consolidated financial statements as of and for the year ended December 31, 2021 and each of the quarters during the year ended December 31, 2021 on Form 10-K/A for the year ended December 31, 2021.

The restatement tables below present a reconciliation from the previously reported to the restated values as of and for the three months ended March 31, 2020. The values as previously reported were derived from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed on May 17, 2021.

CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, 2020

	As previously		Restatement
	Reported		Impacts			As Restated
Income tax provision	$	5,000	$	247,000		$	252,000
Net income	$	539,000	$	(247,000	)	$	292,000
Basic and diluted net income per share	$	0.07	$	(0.03	)	$	0.04

CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS

For the Three Months Ended March 31, 2020

Net income	$	539,000	$	(247,000	)	$	292,000
Change in: Income taxes receivable/payable	$	5,000	$	247,000		$	252,000

Item 2. Management Discussion and Analysis of Financial Condition and Results of Operations.

Critical Accounting Policies

The Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America.  As such, some accounting policies have a significant impact on amounts reported in the Condensed Consolidated Financial Statements.  A summary of those significant accounting policies can be found in Note B to the Consolidated Financial Statements, in our 2021 Annual Report on Form 10-K.  In particular, judgment is used in areas such as determining and assessing possible asset impairments, including investments in, and advances, to unconsolidated entities.

15

The following discussion and analysis provides information which the Company’s management believes is relevant to an assessment and understanding of the Company’s results of operations and financial condition. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and notes thereto appearing elsewhere herein.

Recent events

The recent outbreak of the novel coronavirus COVID-19 has spread across the globe and has been declared a public health emergency by the World Health Organization and a National Emergency by the President of the United States.  Most states and municipalities in the U.S., including California, and Florida, have taken aggressive measures to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing “shelter-in-place” orders, which direct individuals to shelter at their places of residence (subject to limited exceptions).  Across the healthcare industry, resources are being prioritized for the treatment and management of the outbreak.  Consequently, there are delays in delivering radiation therapy treatments.  In addition, the COVID-19 pandemic poses the risk that the Company and its employees, contractors, customers, government and third party payors and others may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that have been and may continue to be requested or mandated by governmental authorities.

While the healthcare treatments that are provided by the Company are generally critical to the well-being of the patients it serves, a  sustained COVID-19 pandemic, and continued measures by the government and industry to contain the pandemic, could negatively impact results for the following reasons: (i) operations at medical facilities, including those operated by the Company, could be subject to reduced operation or prolonged closure; (ii) medical facilities may defer Gamma Knife and other cancer therapy treatments for non-urgent patient cases in order to allocate resources to the care of patients with COVID-19; (iii) patients may defer or cancel treatments due to real or perceived concerns about the potential spread of COVID-19 in a medical facility setting; (iv) the outbreak could materially impact operations for a sustained period of time due to the current travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns; and/or (v) members of the Company’s workforce may become ill or have family members who are ill and are absent as a result, or they may elect not to come to work due to the illness affecting others in our office or facilities.

16

The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 outbreak and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition.  The extent to which the COVID-19 outbreak impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. Although the Company’s contract with its only customer ended in March 2021, the Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $1.6 million at March 31, 2022, will allow the Company the opportunity do so.  Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.  In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.

Results of Operations

Three Months Ended March 31, 2022, Compared to Three Months Ended March 31, 2021

Patient revenue for the three months ended March 31, 2022, and 2021 was $0 and $1,061,000, respectively. Prior to the termination of the Company’s contract with NYU in March 2021, the Company’s Gamma Knife facility at NYU Medical Center represented all of the Company’s patient revenue.

Patient expenses for the three months ended March 31, 2022, were $0 as compared to $86,000 reported for the comparable period in the previous year, primarily due to the annualized effects of the NYU contract ending in March 2021.

Selling, general and administrative expense of $360,000 for the first quarter of 2022 was 19% higher than the $298,000 incurred during the comparable period in 2021, due mostly to lower accounting fees in 2022 offset by a $100,000 gain on termination of the NYU contract during the three months ended March 31, 2021.

The Company incurred no interest expense in the first quarter of 2022 and $2,000 in the comparable period in 2021 related to finance leases.

The Company earned $0 and $8,000 of interest income from its investment in a sales-type sublease for the three months ended March 31, 2022, and 2021, respectively.

During the three months ended March 31, 2022, the Company recognized a $133,000 loss from its investment in unconsolidated entities compared to a $139,000 loss during the same period in 2021. The lower current quarter loss is primarily due to a decrease of advances made to its unconsolidated entities and associated allowances.

During the three months ended March 31, 2021, the Company recognized an income tax provision of $2,000 compared to an income tax provision of $252,000 (restated) during the same period in 2021.

For the three months ended March 31, 2022, the Company reported a net loss of $421,000 as compared to $292,000 (restated) net income for the same period a year earlier. The net loss was primarily due to the termination of the NYU contract.

17

Liquidity and Capital Resources

At March 31, 2021, the Company had working capital of $1,128,000 as compared to $1,918,000 at December 31, 2021. Cash and cash equivalents at March 31, 2022 were $1,658,000 as compared to $2,178,000 at December 31, 2021.

Net cash used in operating activities for the three months ended March 31, 2022, was $336,000 as compared to $214,000 provided by operating activities for the same period a year earlier. This change is primarily due to the termination of the NYU contract and the Company using cash reserves for day to day expenses. During the first quarter of 2022, the Company received $11,000 of distributed earnings from, unconsolidated entities with no corresponding cash receipts in the first quarter of 2021.

With respect to investing activities, the Company made $182,000 of advances to unconsolidated entities during the three months ended March 31, 2022, compared with $144,000 of loans and advances in the same period a year earlier to NP, CGK, CBOP, and MOP to assist with business operations and working capital requirements. The Company also received $532,000 in principal payments under the NYU sales-type sublease in 2021, compared to $0 during the first quarter of 2022.

With respect to financing activities, the Company’s contract with the NYU Medical Center ended in March 2021 along with all related lease arrangements.  The Company paid $89,000 towards its finance lease obligations during the three months ended March 31, 2021.The Company is actively seeking new business ventures that could require investment beyond its current cash reserves.  Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.

Risk Factors

We desire to take advantage of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  The factors listed under the caption “Risk Factors” in Annual Report on our Form 10-K for the fiscal year ended December 31, 2020, have affected or could affect our actual results and could cause such results to differ materially from those expressed in any forward-looking statements made by us.  Investors should carefully consider these risks and speculative factors inherent in and affecting our business and an investment in our common stock.

Disclosure Regarding Forward Looking Statements

The Securities and Exchange Commission encourages companies to disclose forward looking information so that investors can better understand a company’s future prospects and make informed investment decisions.  This document contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues and cash flow.  Words such as “anticipates,” “estimates,” “expects,” “projects,” “targets,” “intends,” “plans,” “believes,” “will be,” “will continue,” “will likely result,” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements.  Those forward-looking statements are based on management’s present expectations about future events.  As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of such changes, new information, future events or otherwise.

18

The Company operates in a highly competitive and rapidly changing environment and in businesses that are dependent on our ability to: achieve profitability; increase revenues; sustain our current level of operations; maintain satisfactory relations with business partners; attract and retain key personnel; maintain and expand our strategic alliances; and protect our intellectual property.  The Company’s actual results could differ materially from management’s expectations because of changes in such factors.  New risk factors can arise and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Investors should also be aware that while the Company might, from time to time, communicate with securities analysts, it is against the Company’s policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, investors should not assume that the Company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others.  Thus, to the extent that reports issued by securities analysts or others contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

In addition, the Company’s overall financial strategy, including growth in operations, maintaining financial ratios and strengthening the balance sheet, could be adversely affected by increased interest rates, construction delays or other transactions, economic slowdowns and changes in the Company’s plans, strategies and intentions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

19

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  We do realize that we are a very small company and as a small company with only the officers and directors participating in the day to day management, with the ability to override controls, each officer and director has multiple positions and responsibilities that would normally be distributed among several employees in larger organizations with adequate segregation of duties to ensure the appropriate checks and balances.  Because the Company does not currently have a separate chief financial officer, the Chief Executive Officer performs these functions with the support of one of the Company’s outside directors who assists in the reporting and disclosure process (the “Lead Director”).

Our management evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report.  Based upon that evaluation, the Company’s Chief Executive Officer concluded that the Company’s disclosure controls and procedures were not effective as of the end of the period covered by this report for the information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended, to be recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, due to the material weakness in internal control over financial reporting described below.

Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934).  Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.  The Company’s internal control over financial reporting includes those policies and procedures that:

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

20

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2022. A material weakness is a control deficiency, or a combination of control deficiencies in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the assessment described above, management identified the following material weakness as of March 31, 2022: The Company did not maintain sufficient qualified personnel with the appropriate level of knowledge, experience and training in the application of accounting principles generally accepted in the United States of America and in internal controls over financial reporting commensurate with its financial reporting requirements. Specifically, effective controls were not designed and in place to ensure that the Company maintained, or had access to, appropriate resources with adequate experience and expertise in the area of financial reporting for transactions such as investments in unconsolidated entities, related party receivables, impairments, lease accounting, accounting for business combinations, income taxes, and to properly assess the application of new accounting pronouncements. The Company is in the process of developing efficient approaches to remediate this material weakness.  To do this in a cost-effective manner, considering the current extent of the Company’s operations, management is making arrangements with consultants and advisors to assist on an as-needed basis.

Changes in Internal Control over Financial Reporting

While there have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended March 31, 2022, management is in the process of developing plans to remediate the material weakness identified above.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

21

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

31.1       Certification of President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1       Certification of President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

101        Interactive Data Files providing financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 in XBRL (eXtensible Business Reporting Language).  Pursuant to Regulation 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability.

22

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	U.S. NeuroSurgical Holdings, Inc.
	(Registrant)
Date: June 24, 2022	By:	/s/ Alan Gold
		Alan Gold
		Director, President and Chief Executive Officer
		and
		Principal Financial Officer of the Registrant

23

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER

(PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER)

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Alan Gold, certify that:

1. I have reviewed this Report on Form 10-Q of U.S. NeuroSurgical Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and;

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  June 24, 2022	/s/ Alan Gold
	Alan Gold
	President & Chairman of the Board
	(Principal Executive Officer and Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

Certificate pursuant to 18 U.S.C. Section 1350,

as adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of U.S. NeuroSurgical Holdings, Inc. on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan Gold, President and Chief Executive Officer of U.S. NeuroSurgical Holdings, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of U.S. NeuroSurgical Holdings, Inc.

/s/ Alan Gold

Alan Gold

President and Chief Executive Officer

(Principal Executive Officer and Principal Financial Officer)

Date: June 24, 2022

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2022 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	0-15586
Entity Registrant Name	U.S. NeuroSurgical Holdings, Inc.
Entity Central Index Key	0001089815
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-5370333
Entity Address, Address Line One	2400 Research Blvd, Suite 325
Entity Address, City or Town	Rockville
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20850
City Area Code	301
Local Phone Number	208-8998
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	7,792,185

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,658,000	$ 2,178,000
Other current assets	47,000	65,000
Total current assets	1,705,000	2,243,000
Other assets:
Due from related parties	965,000	930,000
Investments in unconsolidated entities	146,000	141,000
Goodwill	315,000	315,000
Total other assets	1,426,000	1,386,000
Property and equipment:
Operating lease right-of-use asset	49,000	59,000
Total property and equipment	49,000	59,000
TOTAL ASSETS	3,180,000	3,688,000
Current liabilities:
Operating lease right-of-use liability - current portion	44,000	43,000
Accounts payable and accrued expenses	177,000	170,000
Income taxes payable	403,000	114,000
Total current liabilities	624,000	327,000
Operating lease right-of-use liability - net of current portion	12,000	23,000
Guarantee liability	11,000	11,000
Total liabilities	647,000	361,000
EQUITY
Common stock - par value $.01; 25,000,000 shares authorized; 7,792,185 shares issued and outstanding at March 31, 2022 and December 31, 2021.	78,000	78,000
Additional paid-in capital	2,871,000	2,871,000
Accumulated deficit	(794,000)	(119,000)
U.S. Neurosurgical Holdings, Inc. stockholders' equity	2,155,000	2,830,000
Noncontrolling interests	378,000	497,000
Total equity	2,533,000	3,327,000
TOTAL LIABILITIES AND EQUITY	$ 3,180,000	$ 3,688,000

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
STOCKHOLDERS' EQUITY
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	7,792,185	7,792,185
Common stock, shares outstanding (in shares)	7,792,185	7,792,185

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 0	$ 1,061,000
Costs and expenses:
Patient expenses	0	86,000
Selling, general and administrative	360,000	298,000
Total	360,000	384,000
Operating (loss) income	(360,000)	677,000
Total other (expense) income
Interest expense	0	(2,000)
Interest income - sales-type sublease	0	8,000
Loss from investments in unconsolidated entities, net	(133,000)	(139,000)
Total other expense	(133,000)	(133,000)
(Loss) income before income taxes	(493,000)	544,000
Provision for income taxes	2,000	252,000
Net (loss) income	(495,000)	292,000
Net loss attributable to noncontrolling interests	74,000	0
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc.	$ (421,000)	$ 292,000
Basic net (loss) income per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share)	$ (0.05)	$ 0.04
Diluted net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.05)	$ 0.04
Weighted average common shares outstanding, basic (in shares)	7,792,185	7,792,185
Weighted average common shares outstanding, diluted (in shares)	7,792,185	7,792,185

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (495,000)	$ 292,000
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Amortization of operating lease right-of-use asset	10,000	8,000
Loss from investments in unconsolidated entities, net	133,000	139,000
Distributed earnings from unconsolidated entities	11,000	0
Deferred income taxes	0	0
Changes in:
Accounts receivable	0	(482,000)
Income taxes receivable/payable	(11,000)	252,000
Other current assets	18,000	19,000
Accounts payable and accrued expenses	8,000	(4,000)
Operating lease right-of-use liability	(10,000)	(10,000)
Net cash (used in) provided by operating activities	(336,000)	214,000
Cash flows from investing activities:
Advances to unconsolidated entities	(182,000)	(144,000)
Capital contributions to unconsolidated entities	(2,000)	0
Principal payments received under sales-type sublease	0	532,000
Net cash (used in) provided by investing activities	(184,000)	388,000
Cash flows from financing activities:
Repayment of finance lease obligations	0	(89,000)
Net cash used in financing activities	0	(89,000)
Net change in cash and cash equivalents	(520,000)	513,000
Cash and cash equivalents - beginning of period	2,178,000	2,030,000
Cash and cash equivalents - end of period	1,658,000	2,543,000
Cash paid for:
Interest	$ 0	$ 2,000

XML

Basis of Preparation

3 Months Ended

Mar. 31, 2022

Basis of Preparation [Abstract]

Basis of Preparation

Note A - Basis of Preparation

The accompanying Condensed Consolidated Financial Statements of U.S. NeuroSurgical Holdings, Inc. and Subsidiaries (the “Company”) as of March 31, 2021, and 2020, are unaudited.  However, in the opinion of management, such statements include all adjustments necessary for a fair statement of the information presented therein.  The Consolidated Balance Sheet at December 31, 2021, has been derived from the audited Consolidated Financial Statements at that date appearing in the Company’s Annual Report on Form 10-K.

Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements.  Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements.

Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years.  The only change to the Company’s equity in the three months ended March 31, 2022, and 2021 was net (loss) income for the periods.

The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation to noncontrolling interests in consolidated financial statements.  The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent’s equity and purchases and sales of equity interests, that do not result in a change in control, to be accounted for as equity transactions.  In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income.

The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification (“ASC”) Topic 842, Leases.

The Company primarily generated revenue, in 2021, from a leasing arrangement with New York University, which is not within the scope of Revenue from Contracts with Customers (Topic 606), and from the sale of maintenance, under the same agreement, with a single performance obligation. The NYU agreement ended in March 2021.

The tables below present financial information associated with our leases.

	Classification	March 31, 2022		March 31, 2021
Assets
Long-term
Operating lease assets	Operating lease right-of-use asset	$	49,000	$	86,000
Total leased assets		$	49,000	$	86,000
Liabilities
Current
Operating lease liabilities	Operating lease right-of-use liability - current portion	$	44,000	$	40,000
Long-term
Operating lease liabilities	Operating lease right-of-use liability - net of current portion	$	12,000	$	56,000
Total lease liabilities		$	56,000	$	96,000
Lease Cost
Operating lease cost	Selling, general and administrative	$	10,000	$	11,000
Finance lease cost
Interest on lease liabilities	Interest expense		-		2,000
Sublease income	Interest income - sales-type sublease		-		8,000
Net lease expense		$	10,000	$	5,000

Maturity of lease liabilities (as of March 31, 2022)	Operating lease
2022		33,000
2023		25,000
Total	$	58,000
Less amount representing interest		2,000
Present value of lease liabilities	$	56,000
Discount rate		5.850	%

XML

Gamma Knife at NYU Medical Center

3 Months Ended

Mar. 31, 2022

Gamma Knife at NYU Medical Center [Abstract]

Gamma Knife at NYU Medical Center

Note B – Gamma Knife at NYU Medical Center

U.S. NeuroSurgical, Inc. (“USN”), a wholly-owned subsidiary of U.S. NeuroSurgical Holdings, Inc., opened a New York gamma knife treatment center in July 1997 on the campus of New York University (“NYU”) Medical Center.   The Company’s contract with NYU, its only customer, ended in March 2021.  Upon termination of the NYU contract, the Company recognized a gain of $100,000 relating to previously accrued expenses.  This gain was included as a reduction in selling, general and administrative expense in the quarter ended March 31, 2021.  The Company is actively seeking new business ventures and believes that its cash reserves, which are in excess of $1.6 million at March 31, 2022, will allow the Company the opportunity do so.  Such plans include possible new operations or extensions of its activities in Florida and California, where it has established working relationships with physician groups, hospitals and other organizations.  In addition to these activities, the Company has been exploring possible combinations with other existing businesses that would create a larger operating entity that would better justify the expenses involved in continuing as an independent publicly traded company.

XML

The Southern California Regional Gamma Knife Center

3 Months Ended

Mar. 31, 2022

The Southern California Regional Gamma Knife Center [Abstract]

The Southern California Regional Gamma Knife Center

Note C – The Southern California Regional Gamma Knife Center

During 2007, the Company, through a noncontrolling interest in joint ventures, managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California.  Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife.  CGK leases the gamma knife from NeuroPartners LLC, which holds the gamma knife equipment.  In addition to returns on its ownership interests, USNC expects to receive fees for management services relating to the facility.

USNC is a 20% owner of NeuroPartners LLC and owns 39% of CGK.

USNC was a 20% guarantor on NeuroPartners LLC’s seven-year lease with respect to the gamma knife equipment and certain leasehold improvements at SARH.  In February 2016, NeuroPartners LLC negotiated a new five-year lease to fund the reloading of cobalt and related construction services.  The new lease of $1,663,000 included a balance of $668,000 from the prior lease obligations.  This new lease was payable over 60 months.  The first payment of $31,000 was paid in April 2016 and the final payment was paid in March 2021, removing USNC’s guarantee obligation.

Construction of the SARH gamma knife center was completed in December 2008 and the first patient was treated in January 2009.  The project has been funded principally by outside investors.  While the Company, through its joint ventures, has led the effort in organizing the business and overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal.

At March 31, 2022 and December 31, 2021, the Company’s recorded investment (loss) of NeuroPartners LLC and CGK was $0 and ($10,000), respectively. For the three months ended March 31, 2022, the Company’s equity in income of NeuroPartners LLC and CGK was $10,000 and compared to equity in loss of ($2,000) for the three months ended March 31, 2021.  At March 31, 2022, and December 31, 2021, amounts due from related parties was $19,000 and $6,000, respectively.

The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:

NeuroPartners LLC and CGK Condensed Combined Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	122,000		$	166,000
Net (loss) income	$	(30,000	)	$	19,000
USNC’s equity in income (loss) of NeuroPartners LLC and CGK	$	10,000		$	(2,000	)

NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information

	March 31, 2022		December 31, 2021
Current assets	$	368,000	$	299,000
Noncurrent assets		230,000		294,000
Total assets	$	598,000	$	593,000
Current liabilities	$	598,000	$	564,000
Noncurrent liabilities		-		-
Equity		-		29,000
Total liabilities and equity	$	598,000	$	593,000

XML

Florida Oncology Partners

3 Months Ended

Mar. 31, 2022

Florida Oncology Partners [Abstract]

Florida Oncology Partners

Note D – Florida Oncology Partners

During 2010, through the formation of a joint venture, in which it has a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. In 2010, the Company formed FOP in partnership with local physicians and other investors.  USNC owned a 24% interest in the venture. FOP abandoned its operations on June 28, 2019, due to continued losses at the site and lack of success in good faith efforts to renegotiate the agreement after several months of discussion. Due to the circumstances, FOP derecognized the associated assets and liabilities and calculated a contingent liability equal to the net liabilities derecognized. On November 24, 2021, the third-party owner filed a Voluntary Motion to Dismiss their lawsuit against FOP, and on December 11, 2021, it was accepted and recorded by the court. There can be no guarantee the third-party owner will not reinstitute any future claims against FOP.

The Company’s recorded investment in FOP prior to dissolution had been reduced to zero due to losses incurred in prior years. No equity in earnings had been recorded by the Company due to FOP’s deficit equity.

On September 21, 2021, FOP filed Articles of Dissolution with the Florida Department of State that were recorded on September 22, 2021. FOP is fully dissolved.

XML

Boca Oncology Partners

3 Months Ended

Mar. 31, 2022

Boca Oncology Partners [Abstract]

Boca Oncology Partners

Note E – Boca Oncology Partners

During the quarter ended June 30, 2011, the Company, through the formation of a joint venture, in which it had a noncontrolling interest, participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida.  In June 2011, Boca Oncology Partners RE, LLC (“BOPRE”,) an affiliated entity, purchased a 20% interest in Boca West IMP, owner of a medical office building in West Boca, Florida in which BOP operates.  BOP occupies 6,000 square feet of the 32,000 square foot building.  The Company invested $225,000 initially and had a 22.5% interest in BOP and BOPRE. In February 2014, the Company and other members sold their interests in BOP.

In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP.

During the years ended December 31, 2018 and 2017, several investors relinquished part of their ownership interest in BOPRE, and those interests were distributed among the remaining investors in relationship to their percentages owned. During 2021 and 2022 additional members relinquished its ownership to USNC. As a result, the Company now holds a 24.36% ownership interest in BOPRE, which it accounts for under the equity method. The Company’s recorded investment in BOPRE is $145,000 and $151,000 at March 31, 2022 and December 31, 2021, respectively.

The following tables present the summarized financial information of BOPRE:

BOPRE Condensed Income Statement Information

	Three Months Ended March 31,
	2022			2021
Rental Income		$	-		$	-
Net income		$	17,000		$	18,000
USNC’s equity in earnings of BOPRE		$	4,000		$	3,000

BOPRE Condensed Balance Sheet Information

	March 31, 2022		December 31, 2021
Current assets	$	80,000	$	112,000
Noncurrent assets		757,000		757,000
Total assets	$	837,000	$	869,000
Current liabilities	$	-	$	-
Noncurrent liabilities		-		-
Equity		837,000		869,000
Total liabilities and equity	$	837,000	$	869,000

XML

Medical Oncology Partners

3 Months Ended

Mar. 31, 2022

Medical Oncology Partners [Abstract]

Medical Oncology Partners

Note F - Medical Oncology Partners

In April 2015, MOP, was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in UOMA. USNC was not a member of MOP at the time of formation as it was not able to participate due to the fact that USNC was not a physician. Nevertheless, USNC wished to eventually obtain an equity interest in MOP and loaned Dr. Jaime Lozano, the principal investor in MOP and a co-investor in FOP, $173,000.  Dr. Lozano used these funds, along with an equal amount of his own funds (a total of $345,000), to purchase a 76.67% interest in MOP. Other investors paid a further $105,000 for the remaining equity in MOP. MOP used the $450,000 of financing to acquire a 100% equity interest in UOMA.  An application was filed for a waiver to allow USNC to hold an equity interest notwithstanding the physician requirement and on December 22, 2016, USNC was cleared to become a part owner of MOP. Dr. Lozano agreed to exchange half of his membership interest to USNC in settlement of the note to USNC.  USNC and Dr. Lozano also agreed to share equally in providing a 5% equity interest in MOP to an additional investor as a consulting fee for services rendered in the administration of MOP and UOMA. At December 22, 2016, USNC owned 35.83% of MOP with an initial carrying value of $161,000. The Company recorded its share of losses of $12,000 for the period from December 22, 2016 to December 31, 2016, against its investment which resulted in a reduction of its equity investment to $149,000.

Due to increasing costs, continued net losses since April 2015, and reliance on related party and other debt for operating cash flows, the fair value of UOMA is less than its carrying amount. The Company tested its investment for impairment at December 31, 2016 and determined that the investment was impaired, and an impairment loss was recorded against the entire equity balance in MOP, as well as loans from USN and USNC to MOP and UOMA. For the three months ended March 31, 2022 and 2021, the Company’s equity in loss of MOP was $39,000 and $60,000, respectively, but was not recorded due to prior losses.

During the three months ended March 31, 2022 and 2021, the Company advanced $99,600 and $141,000, all of which has been fully impaired. These allowances and write offs were recorded as losses from investments in unconsolidated entities.

Due to loans made to MOP and UOMA, MOP and UOMA are considered to be variable interest entities of the Company.  However, as the Company is not deemed to be the primary beneficiary of MOP or UOMA, since it does not have the power to direct the operating activities that most significantly affect MOP’s or UOMA’s economic performance, the entities are not consolidated, but certain disclosures are provided herein.

The following table presents the summarized financial information of MOP:

MOP Condensed Consolidated Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	533,000		$	537,000
Net loss	$	(188,000	)	$	(168,000	)
USNC’s equity in loss of MOP	$	(39,000	)	$	(60,000	)

MOP Condensed Consolidated Balance Sheet Information

	March 31, 2022			December 31, 2021
Current assets	$	277,000		$	201,000
Noncurrent assets		300,000			384,000
Total assets	$	577,000		$	585,000
Current liabilities	$	3,229,000		$	3,109,000
Noncurrent liabilities		78,000			92,000
Deficit		(2,730,000	)		(2,616,000	)
Total liabilities and deficit	$	577,000		$	585,000

XML

CB Oncology Partners

3 Months Ended

Mar. 31, 2022

CB Oncology Partners [Abstract]

CB Oncology Partners

Note G - CB Oncology Partners

CBOP was organized September 1, 2017, to acquire the rights of the new center from FOP. USNC originally had a 24% equity interest in CBOP.  Beginning in October of 2017, CBOP began paying the remainder of the costs associated with opening the center. The medical center opened and treated its first patient in January of 2018.

Effective November 15, 2019, FOP transferred to, and CBOP assumed, a loan with BB&T bank, that it had entered into in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. In addition, CBOP and BB&T agreed to reduce the monthly loan repayments for the next nine months, and to extend the term of the loan from November 2024 to July 2025. In July 2020 CBOP and BB&T further agreed to reduce the monthly payments for the life of the loan and extended the loan to July of 2027.

In June 2020, CBOP made a $500,000 capital call to its members. UNSC converted previously-made advances totaling $121,000 into equity in CBOP to meet its capital requirement, and other members contributed $212,000 in cash. The remaining capital contributions are not expected to be met and, accordingly, the Company’s equity interest in CBOP increased to 28.58% in June 2020.

Amounts due from CBOP at March 31, 2022, total $2,208,000 of outstanding principal, less $1,289,000 of allowances, for a net receivable of $919,000 all of which is included in due from related parties on the accompanying Condensed Consolidated Balance Sheets. Amounts due from CBOP at December 31, 2021, total $2,174,000 of outstanding principal, less $1,251,000 of allowances, for a net receivable of $923,000 all of which is included in due from related parties on the accompanying Condensed Consolidated Balance Sheets. These balances accrue interest at 6% per annum. Interest earned by the Company from the amounts owed by CBOP totaled $29,000 and $31,000 for the three months ended March 31, 2022 and 2021, respectively. At March 31, 2022 and December 31, 2021, total accrued interest was $427,000 and $398,000, respectively, all of which has been fully reserved for. The Company recorded increases in the allowance as a component of loss from investments in unconsolidated entities and as a deduction in interest income for interest earned.

Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company.  However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic performance, the entity is not consolidated, but certain disclosures are provided herein.

The following table presents the summarized financial information of CBOP:

CBOP Condensed Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	582,000		$	471,000
Net (loss) income	$	(46,000	)	$	62,000
USNC’s equity in (loss) income of CBOP	$	(13,000	)	$	18,000

CBOP Condensed Balance Sheet Information

	March 31, 2022			December 31, 2021
Current assets	$	582,000		$	400,000
Noncurrent assets		3,515,000			3,667,000
Total assets	$	4,097,000		$	4,067,000
Current liabilities	$	3,533,000		$	3,472,000
Noncurrent liabilities		3,125,000			3,121,000
Deficit		(2,561,000	)		(2,526,000	)
Total liabilities and deficit	$	4,097,000		$	4,067,000

XML

Elite Health

3 Months Ended

Mar. 31, 2022

Elite Health [Abstract]

Elite Health

Note H – Elite Health

Effective October 1, 2021, U.S. NeuroSurgical, Inc. (“USN”), acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation (“Elite Health”.) The transaction with Elite Health was structured as an investment by Elite Health shareholders in USN, and as such did not have an immediate effect on the percentage ownership of the shareholders of the Company.  However, the Company’s interest in USN, which currently holds substantially all of the interest in the Company’s businesses and operations, was effectively diluted by 15% as a result of the issuance of the new USN shares to the former holders of Elite Health.  In addition, pursuant to the terms of this transaction, the former shareholders of Elite Health may request that the Company take steps that would give such holders access to the public trading market.  If this is requested by the Elite Health holders, it could be accomplished at the Company’s election through an exchange of such holders’ shares in USN for common stock of the Company.

Elite Health is a private company with a limited operating history.  It was formed in 2017 with the purpose of establishing a managed care organization that will operate as a Medicare Advantage plan for seniors.  It is expected that Elite Health will operate in California, initially San Bernadino, Riverside, and Orange Counties, with the objective of addressing the growing number of Medicare eligible seniors in those markets.

Elite Health is in the process of applying for a Knox Keene license to operate a Medicare Advantage plan in California and has taken preliminary steps toward identifying a network of providers who are well-versed in the healthcare needs of seniors in the communities in which they practice.  If Elite Health is successful in obtaining the license, establishing Elite Health as an operating entity will require significant investment not currently available to the Company.  The Company is currently exploring opportunities to provide the necessary funding to proceed with activities required to launch Elite Health.

XML

Income Taxes

3 Months Ended

Mar. 31, 2022

Income Taxes [Abstract]

Income Taxes

Note I – Income Taxes

The Company’s income tax rate, which includes federal and state income taxes, was approximately 1%, for the three months ended March 31, 2022, and 2021. The Company recorded a tax provision of $2,000 and $252,000 (restated) for the three months ended March 31, 2022, and 2021, respectively.

XML

Restatement of Previously Issued Financial Statements

3 Months Ended

Mar. 31, 2022

Restatement of Previously Issued Financial Statements [Abstract]

Restatement of Previously Issued Financial Statements

Note J - Restatement of Previously Issued Financial Statements

During the quarter ended March 31, 2022, the Company determined that in March 2021, pursuant to an agreement with New York University ("NYU"), ownership of all of the gamma knife equipment at the NYU Medical Center transferred from the Company to NYU, resulting in the recognition of a gain on the sale and transfer of the gamma knife property on the Company's December 31, 2021 income tax returns. The Company previously received insurance proceeds with the Gamma Knife facility, which was destroyed as a result of flooding from Hurricane Sandy. For tax purposes, the resulting gain becomes taxable when the replacement property is sold or disposed of, which occurred in 2021. As a result, the Company recorded this tax liability and restated its consolidated financial statements as of and for the year ended December 31, 2021 and each of the quarters during the year ended December 31, 2021 on Form 10-K/A for the year ended December 31, 2021.

The restatement tables below present a reconciliation from the previously reported to the restated values as of and for the three months ended March 31, 2020. The values as previously reported were derived from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed on May 17, 2021.

CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, 2020

	As previously		Restatement
	Reported		Impacts			As Restated
Income tax provision	$	5,000	$	247,000		$	252,000
Net income	$	539,000	$	(247,000	)	$	292,000
Basic and diluted net income per share	$	0.07	$	(0.03	)	$	0.04

CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS

For the Three Months Ended March 31, 2020

Net income	$	539,000	$	(247,000	)	$	292,000
Change in: Income taxes receivable/payable	$	5,000	$	247,000		$	252,000

XML

Basis of Preparation (Tables)

3 Months Ended

Mar. 31, 2022

Basis of Preparation [Abstract]

Financial Information Associated with our Leases

The tables below present financial information associated with our leases.

	Classification	March 31, 2022		March 31, 2021
Assets
Long-term
Operating lease assets	Operating lease right-of-use asset	$	49,000	$	86,000
Total leased assets		$	49,000	$	86,000
Liabilities
Current
Operating lease liabilities	Operating lease right-of-use liability - current portion	$	44,000	$	40,000
Long-term
Operating lease liabilities	Operating lease right-of-use liability - net of current portion	$	12,000	$	56,000
Total lease liabilities		$	56,000	$	96,000
Lease Cost
Operating lease cost	Selling, general and administrative	$	10,000	$	11,000
Finance lease cost
Interest on lease liabilities	Interest expense		-		2,000
Sublease income	Interest income - sales-type sublease		-		8,000
Net lease expense		$	10,000	$	5,000

Maturity of Lease Liabilities

Maturity of lease liabilities (as of March 31, 2022)	Operating lease
2022		33,000
2023		25,000
Total	$	58,000
Less amount representing interest		2,000
Present value of lease liabilities	$	56,000
Discount rate		5.850	%

XML

The Southern California Regional Gamma Knife Center (Tables)

3 Months Ended

Mar. 31, 2022

Neuro Partners LLC and CGK [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:

NeuroPartners LLC and CGK Condensed Combined Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	122,000		$	166,000
Net (loss) income	$	(30,000	)	$	19,000
USNC’s equity in income (loss) of NeuroPartners LLC and CGK	$	10,000		$	(2,000	)

NeuroPartners LLC and CGK Condensed Combined Balance Sheet Information

	March 31, 2022		December 31, 2021
Current assets	$	368,000	$	299,000
Noncurrent assets		230,000		294,000
Total assets	$	598,000	$	593,000
Current liabilities	$	598,000	$	564,000
Noncurrent liabilities		-		-
Equity		-		29,000
Total liabilities and equity	$	598,000	$	593,000

XML

Boca Oncology Partners (Tables)

3 Months Ended

Mar. 31, 2022

Boca Oncology Partners RE, LLC ("BOPRE") [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the summarized financial information of BOPRE:

BOPRE Condensed Income Statement Information

	Three Months Ended March 31,
	2022			2021
Rental Income		$	-		$	-
Net income		$	17,000		$	18,000
USNC’s equity in earnings of BOPRE		$	4,000		$	3,000

BOPRE Condensed Balance Sheet Information

	March 31, 2022		December 31, 2021
Current assets	$	80,000	$	112,000
Noncurrent assets		757,000		757,000
Total assets	$	837,000	$	869,000
Current liabilities	$	-	$	-
Noncurrent liabilities		-		-
Equity		837,000		869,000
Total liabilities and equity	$	837,000	$	869,000

XML

Medical Oncology Partners (Tables)

3 Months Ended

Mar. 31, 2022

Medical Oncology Partners LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following table presents the summarized financial information of MOP:

MOP Condensed Consolidated Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	533,000		$	537,000
Net loss	$	(188,000	)	$	(168,000	)
USNC’s equity in loss of MOP	$	(39,000	)	$	(60,000	)

MOP Condensed Consolidated Balance Sheet Information

	March 31, 2022			December 31, 2021
Current assets	$	277,000		$	201,000
Noncurrent assets		300,000			384,000
Total assets	$	577,000		$	585,000
Current liabilities	$	3,229,000		$	3,109,000
Noncurrent liabilities		78,000			92,000
Deficit		(2,730,000	)		(2,616,000	)
Total liabilities and deficit	$	577,000		$	585,000

XML

CB Oncology Partners (Tables)

3 Months Ended

Mar. 31, 2022

CB Oncology Partners LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following table presents the summarized financial information of CBOP:

CBOP Condensed Income Statement Information

	Three Months Ended March 31,
	2022			2021
Patient revenue	$	582,000		$	471,000
Net (loss) income	$	(46,000	)	$	62,000
USNC’s equity in (loss) income of CBOP	$	(13,000	)	$	18,000

CBOP Condensed Balance Sheet Information

	March 31, 2022			December 31, 2021
Current assets	$	582,000		$	400,000
Noncurrent assets		3,515,000			3,667,000
Total assets	$	4,097,000		$	4,067,000
Current liabilities	$	3,533,000		$	3,472,000
Noncurrent liabilities		3,125,000			3,121,000
Deficit		(2,561,000	)		(2,526,000	)
Total liabilities and deficit	$	4,097,000		$	4,067,000

XML

Restatement of Previously Issued Financial Statements (Tables)

3 Months Ended

Mar. 31, 2022

Restatement of Previously Issued Financial Statements [Abstract]

Reconciliation from the Previously Reported to the Restated Values

The restatement tables below present a reconciliation from the previously reported to the restated values as of and for the three months ended March 31, 2020. The values as previously reported were derived from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed on May 17, 2021.

CONDENSED CONSOLIDATD STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, 2020

	As previously		Restatement
	Reported		Impacts			As Restated
Income tax provision	$	5,000	$	247,000		$	252,000
Net income	$	539,000	$	(247,000	)	$	292,000
Basic and diluted net income per share	$	0.07	$	(0.03	)	$	0.04

CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS

For the Three Months Ended March 31, 2020

Net income	$	539,000	$	(247,000	)	$	292,000
Change in: Income taxes receivable/payable	$	5,000	$	247,000		$	252,000

XML

Basis of Preparation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Long-term Assets [Abstract]
Operating lease right-of-use asset	$ 49,000	$ 86,000	$ 59,000
Total leased assets	49,000	86,000
Current Liabilities [Abstract]
Operating lease right-of-use liability - current portion	44,000	40,000	43,000
Long-term Liabilities [Abstract]
Operating lease right-of-use liability - net of current portion	12,000	56,000	$ 23,000
Total lease liabilities	56,000	96,000
Lease Cost [Abstract]
Net lease expense	10,000	5,000
Operating lease [Abstract]
2022	33,000
2023	25,000
Total	58,000
Less amount representing interest	2,000
Present value of lease liabilities	$ 56,000
Discount rate	5.85%
Selling, General and Administrative Expenses [Member]
Lease Cost [Abstract]
Operating lease cost	$ 10,000	11,000
Interest Expense [Member]
Lease Cost [Abstract]
Finance lease cost, interest on lease liabilities	0	2,000
Interest Income - Sales-type Sublease [Member]
Lease Cost [Abstract]
Sublease income	$ 0	$ 8,000

XML

Gamma Knife at NYU Medical Center (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Gamma Knives at NYU Medical Center [Abstract]
Cash reserves	$ 1,658,000	$ 2,178,000
NYU [Member]
Gamma Knives at NYU Medical Center [Abstract]
Gain on termination of contract	100,000
NYU [Member] | Minimum [Member]
Gamma Knives at NYU Medical Center [Abstract]
Cash reserves	$ 1,600,000

XML

The Southern California Regional Gamma Knife Center (Details)		3 Months Ended			12 Months Ended
	Apr. 01, 2016 USD ($)	Mar. 31, 2022 USD ($) Payment	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Feb. 29, 2016 USD ($)
The Southern California Regional Gamma Knife Center [Abstract]
Renovation installation and operation agreement period		14 years
Lease payment		$ 0	$ 89,000
Condensed Income Statement Information [Abstract]
Patient revenue		0	1,061,000
Net (loss) income		(495,000)	292,000	$ 292,000
USNC's equity in earnings (loss)		(133,000)	(139,000)
Condensed Balance Sheet Information [Abstract]
Current assets		1,705,000			$ 2,243,000
TOTAL ASSETS		3,180,000			3,688,000
Current liabilities		624,000			327,000
Equity		2,533,000			3,327,000
TOTAL LIABILITIES AND EQUITY		3,180,000			3,688,000
Neuro Partners LLC and CGK [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Recorded amount of equity method income		0			10,000
Condensed Income Statement Information [Abstract]
Patient revenue		122,000	166,000
Net (loss) income		(30,000)	19,000
Condensed Balance Sheet Information [Abstract]
Current assets		368,000			299,000
Noncurrent assets		230,000			294,000
TOTAL ASSETS		598,000			593,000
Current liabilities		598,000			564,000
Noncurrent liabilities		0			0
Equity		0			29,000
TOTAL LIABILITIES AND EQUITY		$ 598,000			593,000
Neuro Partners LLC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		20.00%
Neuro Partners LLC [Member] | Lease One [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Share of guarantee in lease obligations		20.00%
Lease term		7 years
Lease obligation						$ 668,000
Neuro Partners LLC [Member] | Lease Two [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Lease term		5 years
Lease obligation						$ 1,663,000
Number of lease payments | Payment		60
Lease payment	$ 31,000
CGK [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		39.00%
Due from related parties		$ 19,000			$ 6,000
Neuro Partners LLC and CGK [Member]
Condensed Income Statement Information [Abstract]
USNC's equity in earnings (loss)		$ 10,000	$ (2,000)

XML

Florida Oncology Partners (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Florida Oncology Partners [Abstract]
Recorded distribution	$ 11,000	$ 0
Investments in unconsolidated entities	146,000		$ 141,000
FOP [Member]
Florida Oncology Partners [Abstract]
Recorded distribution	0
Investments in unconsolidated entities	$ 0
FOP [Member] | USNC [Member]
Florida Oncology Partners [Abstract]
Ownership percentage	24.00%

XML

Boca Oncology Partners (Details)	1 Months Ended		3 Months Ended
	Jun. 30, 2012	Jun. 30, 2011 USD ($)	Mar. 31, 2022 USD ($) ft²	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)
Boca Oncology Partners [Abstract]
Recorded investments			$ 146,000			$ 141,000
Condensed Income Statement Information [Abstract]
Net income			(495,000)	$ 292,000	$ 292,000
USNC's equity in earnings (loss)			(133,000)	(139,000)
Condensed Balance Sheet Information [Abstract]
Current assets			1,705,000			2,243,000
TOTAL ASSETS			3,180,000			3,688,000
Current liabilities			624,000			327,000
Equity			2,533,000			3,327,000
TOTAL LIABILITIES AND EQUITY			3,180,000			3,688,000
Boca Oncology Partners RE, LLC ("BOPRE") [Member]
Condensed Income Statement Information [Abstract]
Rental income			0	0
Net income			17,000	18,000
Condensed Balance Sheet Information [Abstract]
Current assets			80,000			112,000
Noncurrent assets			757,000			757,000
TOTAL ASSETS			837,000			869,000
Current liabilities			0			0
Noncurrent liabilities			0			0
Equity			837,000			869,000
TOTAL LIABILITIES AND EQUITY			$ 837,000			$ 869,000
Boca Oncology Partners, LLC [Member]
Boca Oncology Partners [Abstract]
Area of real estate property (in square foot) | ft²			6,000
Boca Oncology Partners RE, LLC ("BOPRE") [Member]
Boca Oncology Partners [Abstract]
Ownership percentage			24.36%			24.36%
Recorded investments			$ 145,000			$ 151,000
Condensed Income Statement Information [Abstract]
USNC's equity in earnings (loss)			$ 4,000	$ 3,000
Boca Oncology Partners RE, LLC ("BOPRE") [Member] | Boca West IMP [Member]
Boca Oncology Partners [Abstract]
Percentage of interest in medical office building		20.00%
Ownership percentage	23.75%
Additional investor purchased ownership percentage	3.75%
BOP and BOPRE [Member]
Boca Oncology Partners [Abstract]
Area of real estate property (in square foot) | ft²			32,000
Investments in unconsolidated entities		$ 225,000
Ownership percentage		22.50%

XML

Medical Oncology Partners (Details) - USD ($)		3 Months Ended
	Dec. 31, 2016	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2021	Dec. 23, 2016
Medical Oncology Partners [Abstract]
Carrying value of investment		$ 146,000			$ 141,000
Advances to unconsolidated entities		182,000	$ 144,000
Condensed Consolidated Income Statement Information [Abstract]
Patient revenue		0	1,061,000
Net loss		(495,000)	292,000	$ 292,000
USNC's equity in (loss) income		(133,000)	(139,000)
Condensed Consolidated Balance Sheet Information [Abstract]
Current assets		1,705,000			2,243,000
TOTAL ASSETS		3,180,000			3,688,000
Current liabilities		624,000			327,000
Deficit		2,533,000			3,327,000
TOTAL LIABILITIES AND EQUITY		3,180,000			3,688,000
MOP [Member]
Condensed Consolidated Income Statement Information [Abstract]
Patient revenue		533,000	537,000
Net loss		(188,000)	(168,000)
Condensed Consolidated Balance Sheet Information [Abstract]
Current assets		277,000			201,000
Noncurrent assets		300,000			384,000
TOTAL ASSETS		577,000			585,000
Current liabilities		3,229,000			3,109,000
Noncurrent liabilities		78,000			92,000
Deficit		(2,730,000)			(2,616,000)
TOTAL LIABILITIES AND EQUITY		$ 577,000			$ 585,000
MOP [Member]
Medical Oncology Partners [Abstract]
Equity interest percentage to be acquired by subsidiary		100.00%
Investments in unconsolidated entities		$ 450,000
Advances to unconsolidated entities		99,600	141,000
Condensed Consolidated Income Statement Information [Abstract]
USNC's equity in (loss) income	$ (12,000)	(39,000)	$ (60,000)
MOP [Member] | Other Investor [Member]
Medical Oncology Partners [Abstract]
Investments in unconsolidated entities		105,000
MOP [Member] | USNC [Member]
Medical Oncology Partners [Abstract]
Investments in unconsolidated entities		173,000
Ownership percentage						35.83%
Carrying value of investment		149,000				$ 161,000
MOP [Member] | USNC [Member] | Dr. Jaime Lozano [Member]
Medical Oncology Partners [Abstract]
Investments in unconsolidated entities		$ 345,000
Ownership percentage		76.67%
Percentage of equity interest to an additional investor as a consulting fee for services		5.00%

XML

CB Oncology Partners (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2021	Sep. 02, 2017
Condensed Income Statement Information [Abstract]
Patient revenue		$ 0	$ 1,061,000
Net (loss) income		(495,000)	292,000	$ 292,000
USNC's equity in (loss) income		(133,000)	(139,000)
Condensed Balance Sheet Information [Abstract]
Current assets		1,705,000			$ 2,243,000
TOTAL ASSETS		3,180,000			3,688,000
Current liabilities		624,000			327,000
Deficit		2,533,000			3,327,000
TOTAL LIABILITIES AND EQUITY		3,180,000			3,688,000
CB Oncology Partners LLC [Member]
Condensed Income Statement Information [Abstract]
Patient revenue		582,000	471,000
Net (loss) income		(46,000)	62,000
Condensed Balance Sheet Information [Abstract]
Current assets		582,000			400,000
Noncurrent assets		3,515,000			3,667,000
TOTAL ASSETS		4,097,000			4,067,000
Current liabilities		3,533,000			3,472,000
Noncurrent liabilities		3,125,000			3,121,000
Deficit		(2,561,000)			(2,526,000)
TOTAL LIABILITIES AND EQUITY		4,097,000			4,067,000
CB Oncology Partners LLC [Member]
CB Oncology Partners [Abstract]
Ownership percentage	28.58%					24.00%
Capital called from members	$ 500,000
Advances converted into equity	121,000
Contribution in cash	$ 212,000
Outstanding amount		2,208,000			2,174,000
Outstanding amount, less allowances		1,289,000			1,251,000
Due from related parties		$ 919,000			923,000
Note bearing interest		6.00%
Interest earned from the amounts owed by entity		$ 29,000	31,000
Accrued interest		427,000			$ 398,000
Condensed Income Statement Information [Abstract]
USNC's equity in (loss) income		$ (13,000)	$ 18,000

XML

Elite Health (Details)	Oct. 01, 2021
Elite Health Plan, Inc. [Member]
Elite Health [Abstract]
Equity consideration, percentage of outstanding shares	15.00%

XML

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Taxes [Abstract]
Federal and state income taxes, rate	1.00%	1.00%
Tax provision	$ 2,000	$ 252,000	$ 252,000

XML

Restatement of Previously Issued Financial Statements, Condensed Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Income tax provision	$ 2,000	$ 252,000	$ 252,000
Net income	$ (495,000)	$ 292,000	$ 292,000
Basic net income per share (in dollars per share)	$ (0.05)	$ 0.04	$ 0.04
Diluted net income per share (in dollars per share)	$ (0.05)	$ 0.04	$ 0.04
As Previously Reported [Member]
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Income tax provision			$ 5,000
Net income			$ 539,000
Basic net income per share (in dollars per share)			$ 0.07
Diluted net income per share (in dollars per share)			$ 0.07
Restatement Impacts [Member]
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Income tax provision			$ 247,000
Net income			$ (247,000)
Basic net income per share (in dollars per share)			$ (0.03)
Diluted net income per share (in dollars per share)			$ (0.03)

XML

Restatement of Previously Issued Financial Statements, Condensed Consolidated Statements of Cash Flows (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]
Net income	$ (495,000)	$ 292,000	$ 292,000
Change in: Income taxes receivable/payable	$ (11,000)	$ 252,000	252,000
As Previously Reported [Member]
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]
Net income			539,000
Change in: Income taxes receivable/payable			5,000
Restatement Impacts [Member]
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]
Net income			(247,000)
Change in: Income taxes receivable/payable			$ 247,000